Melanoma
Conditions
Brief summary
This study is being conducted to explore the efficacy and safety of SHR-1701 combined with temozolomide in the treatment of advanced melanoma.
Detailed description
This trial is a prospective, single-center, single-arm clinical research. Based on current experience, single agent immunotherapy has limited efficacy in advanced melanoma. SHR-1701 is a novel immunotherapy drug . Preclinical data suggest that temozolomide selectively depletes regulatory T cells. This potential immunomodulatory effect of temozolomide provides rationale for combination with SHR-1701. This study is aiming to evaluate the efficacy and safety of SHR-1701 combined with temozolomide in patients with advanced melanoma. The safety and efficacy of this study will be assessed through ORR, DCR,PFS, OS , and adverse effects as graded by CTCAE 5.0.
Interventions
DRUGSHR-1701
SHR-1701 combined with temozolomide
DRUGTemozolomide
SHR-1701 combined with temozolomide
Sponsors
Yong Chen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Has unresectable Stage III or Stage IV or melanoma per American Joint Committee on Cancer (AJCC) staging system version 8. At least one measurable lesion conforming to RECIST 1.1 criteria. * No previously received systematic therapy. * The toxicity of prior treatment has recovered to ≤1 grade according to CTCAE 5.0. * ECOG score 0-1. * The expected survival time is ≥ 12 weeks. * Adequate organ and bone marrow function. * Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before the commencement of the study and the results are negative, and are willing to use a medically approved high potency contraceptive method during the study period and within 3 months after the last administration of the study drug; For male subjects whose partner is a female of childbearing age, they should be surgically sterilized or agree to use an effective method of contraception during the study period and for 3 months after administration of the last study. * Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures.
Exclusion criteria
* History of other malignant tumors, except for cured skin basal cell carcinoma, squamous cell carcinoma of skin, superficial bladder carcinoma, papillary thyroid carcinoma, intraductal carcinoma and cervical carcinoma in situ. * Has ocular melanoma. * The first study drug treatment was less than 4 weeks from the last systematic antitumor therapy or 5 half-lives from the last targeted therapy; less than 4 weeks from major surgery; less than7 days from immunosuppressive drug; less than 3 weeks from immunomodulatory; less than 4 weeks from live attenuated vaccine. * Systemic antibiotic use for 7 days within 4 weeks prior to initial administration, or unexplained fever during screening/prior to initial administration. * With active autoimmune disease or a history of autoimmune disease. * With history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * With immunodeficiency, eg HIV, HBV, HCV. * Have a clear history of serious and uncontrolled other disease or mental disorders. * Has a bleeding tendency or abnormal clotting function. * Subjects with central nervous system disease or brain metastases. * Known to be allergic to the active ingredients or excipients in this study. * Other situations that the researcher considers inappropriate to participate in the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR (Objective Response Rate) | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Containing the incidence of complete response (CR) and partial response (PR). Evaluated according to RECIST 1.1 criteria, subjects received their first tumor imaging evaluation at 6 weeks after the treatment start, followed by imaging evaluation every 2 cycles. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS (Progression-Free-Survival) | From date of treatment start until the date of progression or the date of death due to any cause, assessed up to 12 months | From date of treatment start until the date of progression or the date of death due to any cause. Evaluated according to RECIST 1.1 criteria, subjects received their first tumor imaging evaluation at 6 weeks after the treatment start, followed by imaging evaluation every 2 cycles. |
| DCR (Disease Control Rate) | From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | Containing the incidence of complete response (CR), partial response (PR) and stable disease (SD).Evaluated according to RECIST 1.1 criteria, subjects received their first tumor imaging evaluation at 6 weeks after the treatment start, followed by imaging evaluation every 2 cycles. |
| OS (overall survival) | From date of treatment start until the date of death from any cause or censored at the last day that the subjects are documented to be alive, whichever came first, assessed up to 36 month | From date of treatment start to any cause death or last follow-up. |
| 6mPFS | Up to 6 months | 6-month- Progression-Free-Survival rate. Evaluated according to RECIST 1.1 criteria, subjects received their first tumor imaging evaluation at 6 weeks after the treatment start, followed by imaging evaluation every 2 cycles. |
| Adverse events (per CTCAE v5.0 criteria) | Up to 12months | To evaluate the adverse events of subjects with advanced melanoma after treated with SHR-1701 plus temozolomide |
Countries
China
Contacts
Primary Contactyong chen, MD
Outcome results
None listed